These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16419008)

  • 1. [Hemolytic uremic syndrome].
    Rota S; Cravedi P; Remuzzi G; Ruggenenti P
    G Ital Nefrol; 2005; 22 Suppl 33():S57-64. PubMed ID: 16419008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hemolytic uremic syndrome].
    Mele C; Noris M
    G Ital Nefrol; 2007; 24(1):23-33. PubMed ID: 17342690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
    Polito MG; Kirsztajn GM
    J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy for children with Shiga toxin-E. coli-associated hemolytic uremic syndrome].
    Ito K; Hattori M; Matsumoto N
    Nihon Rinsho; 2002 Jun; 60(6):1126-30. PubMed ID: 12078084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hemolytic uremic syndrome in adults].
    Hertig A; Ridel C; Rondeau E
    Nephrol Ther; 2010 Jul; 6(4):258-71. PubMed ID: 20399168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of hemolytic uremic syndrome after renal transplantation.
    Seitz B; Albano L; Vocila F; Mzoughi S; Aoudia R; Guitard J; Ribes D; Vachet-Copponat H; Mourad G; Bienaimé F; Dahan P; Frémeaux-Bacchi V; Cassuto E
    Transplant Proc; 2007 Oct; 39(8):2583-5. PubMed ID: 17954182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hemolytic-uremic syndrome].
    Bláhová K
    Vnitr Lek; 2004 Jul; 50(7):519-25. PubMed ID: 15323259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation.
    Ferraris JR; Ramirez JA; Ruiz S; Caletti MG; Vallejo G; Piantanida JJ; Araujo JL; Sojo ET
    Pediatr Nephrol; 2002 Oct; 17(10):809-14. PubMed ID: 12376808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background.
    Bresin E; Daina E; Noris M; Castelletti F; Stefanov R; Hill P; Goodship TH; Remuzzi G;
    Clin J Am Soc Nephrol; 2006 Jan; 1(1):88-99. PubMed ID: 17699195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
    Morigi M; Galbusera M; Gastoldi S; Locatelli M; Buelli S; Pezzotta A; Pagani C; Noris M; Gobbi M; Stravalaci M; Rottoli D; Tedesco F; Remuzzi G; Zoja C
    J Immunol; 2011 Jul; 187(1):172-80. PubMed ID: 21642543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans.
    Friedrich AW; Zhang W; Bielaszewska M; Mellmann A; Köck R; Fruth A; Tschäpe H; Karch H
    Clin Infect Dis; 2007 Jul; 45(1):39-45. PubMed ID: 17554698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of typical (enteropathic) hemolytic uremic syndrome.
    Bitzan M; Schaefer F; Reymond D
    Semin Thromb Hemost; 2010 Sep; 36(6):594-610. PubMed ID: 20865636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of the lectin-like domain of thrombomodulin worsens Shiga toxin-associated hemolytic uremic syndrome in mice.
    Zoja C; Locatelli M; Pagani C; Corna D; Zanchi C; Isermann B; Remuzzi G; Conway EM; Noris M
    J Immunol; 2012 Oct; 189(7):3661-8. PubMed ID: 22942429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
    Orth D; Khan AB; Naim A; Grif K; Brockmeyer J; Karch H; Joannidis M; Clark SJ; Day AJ; Fidanzi S; Stoiber H; Dierich MP; Zimmerhackl LB; Würzner R
    J Immunol; 2009 May; 182(10):6394-400. PubMed ID: 19414792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement in typical hemolytic uremic syndrome.
    Orth D; Würzner R
    Semin Thromb Hemost; 2010 Sep; 36(6):620-4. PubMed ID: 20865638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome.
    Richards A; Kathryn Liszewski M; Kavanagh D; Fang CJ; Moulton E; Fremeaux-Bacchi V; Remuzzi G; Noris M; Goodship TH; Atkinson JP
    Mol Immunol; 2007 Jan; 44(1-3):111-22. PubMed ID: 16882452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
    Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.
    Karch H; Friedrich AW; Gerber A; Zimmerhackl LB; Schmidt MA; Bielaszewska M
    Semin Thromb Hemost; 2006 Mar; 32(2):105-12. PubMed ID: 16575685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome.
    Fremeaux-Bacchi V; Moulton EA; Kavanagh D; Dragon-Durey MA; Blouin J; Caudy A; Arzouk N; Cleper R; Francois M; Guest G; Pourrat J; Seligman R; Fridman WH; Loirat C; Atkinson JP
    J Am Soc Nephrol; 2006 Jul; 17(7):2017-25. PubMed ID: 16762990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical hemolytic uremic syndrome: update on the complement system and what is new.
    Hirt-Minkowski P; Dickenmann M; Schifferli JA
    Nephron Clin Pract; 2010; 114(4):c219-35. PubMed ID: 20090363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.